Catalent has announced it has completed the acquisition of Accucaps Industries, a Canada-based developer and manufacturer of Over-the-Counter (OTC), high-potency, and conventional pharmaceutical softgels. Financial details of the transaction have not been disclosed.

The acquisition complements Catalent’s global OTC and prescription pharmaceutical softgel capabilities, as well as capacity, with the addition of a portfolio of products supplied to pharmaceutical companies in North America. Two state-of-the-art facilities were also included, offering integrated softgel development, manufacturing, and packaging, as well as strengthening Catalent’s ability to offer its customers turnkey solutions.

More than 500 Accucaps employees, at two facilities in Windsor and Strathroy, will join Catalent’s global network of 11 Softgel Technologies facilities. The Accucaps facilities house sizeable blistering, bottling and other packaging capabilities, as well as high-potency prescription softgel development and manufacturing expertise that are complementary to Catalent’s.